NEURELIS TO HIGHLIGHT VALTOCO (DIAZEPAM NASAL SPRAY) CIV DEVELOPMENT PROGRAM Updates AT 16TH EILAT CONFERENCE

Company to provide an overview of studies and publications for VALTOCO® in treating episodes of frequent seizure activity (seizure clusters) SAN DIEGO, May 31, 2022 /PRNewswire/ — Neurelis, Inc., today announced it will provide highlights of its clinical development program for VALTOCO®…

Click here to view original post


ADVERTISEMENT — Advertise With Biotech Networks